This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Endo International Résultats passés
Passé contrôle des critères 0/6
Endo International's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 6.8% per year.
Informations clés
-41.7%
Taux de croissance des bénéfices
-40.7%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 6.0% |
Taux de croissance des recettes | -6.8% |
Rendement des fonds propres | n/a |
Marge nette | -121.7% |
Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg
Aug 16Endo International sees 23% rise on 3x higher than normal volume
Aug 03Endo outperforms defying bankruptcy fears and generic entry
Jul 25Endo weighs bankruptcy filing without opioid settlement - WSJ
Jul 12Endo International cools off, giving back some of its 85% Tuesday gain
Jun 29Endo: Stick A Fork In It
May 10Endo: About As Bad As It Gets
Mar 07Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Dec 16Endo: A Win In California But Equity Value Still A Question
Nov 02Endo International: Loses Vasostrict Trial
Aug 31Endo International: Hires Restructuring Advisor
Aug 20Endo International: All About Ongoing Litigation
Aug 07Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road
Jul 15Endo International: Bankruptcy Seems Like The Only Practical Option
Jun 30Endo International wins FDA approval for Micafungin new formulation
Jun 17Endo International plc 2021 Q1 - Results - Earnings Call Presentation
May 07Radius Health partners with Endo unit for abaloparatide in Canada
Jan 05Ventilation des recettes et des dépenses
Comment Endo International gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 2,012 | -2,448 | 568 | 115 |
30 Sep 23 | 2,070 | -252 | 598 | 118 |
30 Jun 23 | 2,160 | -942 | 652 | 118 |
31 Mar 23 | 2,182 | -2,847 | 697 | 119 |
31 Dec 22 | 2,319 | -2,910 | 758 | 121 |
30 Sep 22 | 2,552 | -3,221 | 832 | 129 |
30 Jun 22 | 2,783 | -2,552 | 881 | 123 |
31 Mar 22 | 2,928 | -681 | 870 | 122 |
31 Dec 21 | 2,993 | -569 | 841 | 122 |
30 Sep 21 | 2,964 | 129 | 767 | 147 |
30 Jun 21 | 2,827 | 109 | 687 | 150 |
31 Mar 21 | 2,801 | 137 | 688 | 151 |
31 Dec 20 | 2,903 | 247 | 671 | 120 |
30 Sep 20 | 2,908 | -102 | 661 | 125 |
30 Jun 20 | 3,002 | -75 | 667 | 133 |
31 Mar 20 | 3,014 | -190 | 648 | 129 |
31 Dec 19 | 2,914 | -361 | 632 | 131 |
30 Sep 19 | 2,936 | -418 | 639 | 122 |
30 Jun 19 | 2,952 | -522 | 635 | 125 |
31 Mar 19 | 2,967 | -477 | 630 | 181 |
31 Dec 18 | 2,947 | -962 | 646 | 186 |
30 Sep 18 | 2,929 | -968 | 640 | 209 |
30 Jun 18 | 2,971 | -921 | 612 | 209 |
31 Mar 18 | 3,132 | -1,565 | 620 | 168 |
31 Dec 17 | 3,469 | -1,233 | 615 | 172 |
30 Sep 17 | 3,942 | -4,294 | 666 | 170 |
30 Jun 17 | 4,039 | -4,386 | 717 | 175 |
31 Mar 17 | 4,084 | -3,300 | 754 | 185 |
31 Dec 16 | 4,010 | -3,224 | 771 | 183 |
30 Sep 16 | 3,842 | 553 | 802 | 181 |
30 Jun 16 | 3,704 | -59 | 760 | 158 |
31 Mar 16 | 3,518 | -539 | 721 | 126 |
31 Dec 15 | 3,269 | -300 | 704 | 102 |
30 Sep 15 | 2,858 | -725 | 592 | 89 |
30 Jun 15 | 2,766 | 128 | 649 | 88 |
31 Mar 15 | 2,624 | 260 | 616 | 100 |
31 Dec 14 | 2,381 | 58 | 568 | 113 |
30 Sep 14 | 2,303 | -643 | 609 | 116 |
30 Jun 14 | 2,310 | -637 | 599 | 132 |
31 Mar 14 | 2,429 | -650 | 722 | 135 |
31 Dec 13 | 2,125 | 189 | 574 | 97 |
30 Sep 13 | 2,621 | -628 | 829 | 145 |
30 Jun 13 | 2,711 | -629 | 848 | 157 |
Des revenus de qualité: ENDP.Q is currently unprofitable.
Augmentation de la marge bénéficiaire: ENDP.Q is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ENDP.Q is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.
Accélération de la croissance: Unable to compare ENDP.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ENDP.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Rendement des fonds propres
ROE élevé: ENDP.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.